文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

转甲状腺素蛋白淀粉样变心肌病患者的右心室功能、临床结局及vutrisiran疗效:HELIOS-B随机临床试验的二次分析

Right Ventricular Function, Clinical Outcomes, and Effect of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: Secondary Analysis of the HELIOS-B Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2026-01-01

该研究为HELIOS-B随机临床试验的事后分析,纳入548例有足够超声心动图图像的ATTR-CM患者,中位随访36个月。结果显示右心室功能障碍(以RVFWS≤20%定义)患病率高达85%,且RVFWS及RVFWS/PASP与全因死亡和复发性心血管事件独立相关;vutrisiran在30个月时稳定RVFWS并改善RVFWS/PASP。

要点

  • ATTR-CM患者中右心室功能障碍常见,RVFWS异常者占85%。
  • RVFWS和RVFWS/PASP独立预测全因死亡和复发性心血管事件。
  • vutrisiran可稳定RVFWS并改善RVFWS/PASP,对RVFAC无显著影响。

核心结论

  • RVFWS评估的右心室功能障碍在ATTR-CM中高度 prevalent,独立预测死亡和复发性心血管事件。
  • vutrisiran在30个月时稳定RVFWS并改善RVFWS/PASP。

研究设计与样本

  • HELIOS-B随机临床试验的事后分析,纳入548例有足够超声心动图图像的ATTR-CM患者。
  • 中位随访36个月(IQR 33-36),数据分析时间为2025年9月至12月。
  • 干预为vutrisiran 25 mg皮下注射每12周一次 versus 安慰剂。

主要发现

  • RVFWS异常(绝对值≤20%)者占85%,RV S'≤9.5 cm/s者占56%,RV FAC≤35%者占31%。
  • RVFWS最差四分位组(<10.8%,n=137)估算肾小球滤过率更低、左心室射血分数更低、NAC分期更晚。
  • 更差的RVFWS和RVFWS/PASP与全因死亡和复发性心血管事件风险增加显著相关,独立于临床特征、NAC分期和左心室整体纵向应变。
  • RV S'和RV FAC与结局的关联在多变量调整后减弱。
  • 30个月时vutrisiran组与安慰剂组RVFWS组间差异为1.6%(95%CI 0.7至2.6%),RVFWS/PASP组间差异为+0.08%/mm Hg(95%CI 0.03至0.13),RV FAC组间差异为-1.6%(95%CI -3.7%至0.6%)。

临床怎么用

  • 在ATTR-CM患者中应关注RVFWS评估右心室功能,其独立预后价值优于传统指标RV S'和RV FAC。
  • vutrisiran治疗可稳定RVFWS并改善RVFWS/PASP,支持其对心脏结构和功能的益处。

局限性

  • 本研究为事后分析,仅纳入有足够超声心动图图像的患者(548/655)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Right ventricular (RV) dysfunction is common among patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and portends worse prognosis. The effects of vutrisiran on RV function remain incompletely characterized. OBJECTIVE: To determine the prevalence and prognostic importance of RV dysfunction in ATTR-CM, and to evaluate the effect of vutrisiran on RV function. DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis of the HELIOS-B randomized clinical trial (December 2019 and August 2021) included participants with ATTR-CM who had adequate echocardiographic images. Median (IQR) follow-up was 36 (33-36) months. Data analysis was performed from September to December 2025. INTERVENTIONS: Vutrisiran, 25 mg, subcutaneously every 12 weeks vs placebo. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of all-cause mortality and recurrent cardiovascular events. RV function was assessed using tricuspid annular systolic myocardial velocity (RV S'), RV fractional area change (RV FAC), RV free wall strain (RVFWS), and RVFWS indexed to pulmonary artery systolic pressure (RVFWS/PASP). Associations with outcomes and treatment effects were evaluated. RESULTS: Among 655 participants with ATTR-CM who were randomized, 548 had adequate echocardiographic images. The mean (SD) age was 75 (7) years; 506 patients (92%) were men and 42 (8%) were women. RV dysfunction was more prevalent if defined by abnormal RVFWS (absolute RVFWS ≤20%, 85%) vs RV S' (≤9.5cm/s, 56%) or RV FAC (≤35%, 31%). Patients in the worst RVFWS quartile (<10.8%, n = 137) had lower estimated glomerular filtration rate, lower left ventricular ejection fraction, and more advanced National Amyloidosis Centre (NAC) stage. Worse RVFWS and RVFWS/PASP were significantly associated with greater risk of all-cause mortality and recurrent cardiovascular events, independent of clinical characteristics, NAC stage, and LV global longitudinal strain. In contrast, associations of RV S' and RV FAC with outcomes were attenuated after multivariable adjustment. At 30 months, vutrisiran stabilized RVFWS (between-group difference: 1.6%, 95% CI, 0.7 to 2.6%) and improved RVFWS/PASP compared with placebo (between-group difference: +0.08%/mm Hg; 95% CI, 0.03%/mm Hg to 0.13%/mm Hg), with no significant effect on RV FAC (-1.6%; 95% CI, -3.7% to 0.6%). CONCLUSIONS AND RELEVANCE: RV dysfunction assessed by RVFWS is highly prevalent in ATTR-CM and independently predicts mortality and recurrent CV events, whereas conventional RV measures may underestimate RV dysfunction and lack independent prognostic value. This study found that, consistent with its beneficial effects on other measures of cardiac structure and function, vutrisiran stabilized RVFWS and improved RVFWS/PASP at 30 months. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04153149.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Jering KS, Manafi A, Claggett BL, et al. Right Ventricular Function, Clinical Outcomes, and Effect of Vutrisiran in Transthyretin Amyloidosis With Cardiomyopathy: Secondary Analysis of the HELIOS-B Randomized Clinical Trial. JAMA Cardiol. 2026. PMID: 42646924. doi:10.1001/jamacardio.2026.3390

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。